Help us: Donate
Follow us on:



Bacteria-Based Nanomachine for Targeted Drug Delivery


A group of researchers has succeeded in engineering a new kind of microscopic bio-object that may one day be used for personalized diagnostics and targeted delivery of drugs. The object consists of a genetically modified E. coli bacterium and nanoerythrosomes (small vesicles made of red blood cells), and it demonstrates a substantial improvement in motility over previous designs [1].


Nanomedicine strives to create methods for targeted diagnostics, monitoring, and therapy on a cellular level. Such objects could potentially act upon chemical signals to patrol our body for any signs of disease and/or deliver therapy directly to affected cells (see our recent report on DNA origami nanorobots). One of these avenues of exploration involves objects called “biohybrid microswimmers”, in which living bacteria are used for navigation and propulsion.

Why bacteria?

Bacteria are no strangers to our body: there are at least as many  bacteria in our body as our own cells [2]. Many types of bacteria are nontoxic and non-immunogenic; the human immune system does not react to them. Being living creatures, bacteria can navigate towards stimuli such as food sources, light, oxygen, or, in the case of anaerobic bacteria, a lack thereof. On their way, bacteria are able to penetrate tissues and squeeze through extremely tight passages. Moreover, scientists have found that some bacteria can be steered from outside the body by acoustic waves or a magnetic field and can be made easily detectable in the body for diagnostic and monitoring purposes [3].

Several decades ago, it was discovered that strictly anaerobic bacteria looking for oxygen-free environments and food accumulate in the vicinity of hypoxic and necrotic regions of solid tumors. This led to experiments in cancer bacteriotherapy. Along the way, scientists had realized that genetic modifications can increase the therapeutic effect of bacteria, such as by making them produce certain chemicals. Genetically recombinant bacteria have since been used for the treatment of cancer, diabetes, viral infections, and other pathologies, with numerous treatments reaching clinical trials [4].

The next logical step was to make bacteria deliver any kind of payload in external packages. For a few years, scientists have been producing promising designs by chemically attaching microparticles to flagellated bacteria such as the ubiquitous E.coli.

RBCs as cargo containers

Red blood cells (RBCs), or erythrocytes, have been tested as cargo containers. These cells are naturally adapted to delivering payloads: as they mature, their organelles disappear, and the cells basically become pouches in which hemoglobin-attached oxygen molecules are stored as they are distributed to the tissues. The idea is to replace RBCs’ cytoplasmic content with drug molecules and superparamagnetic iron oxide nanoparticles (SPIONS) that enable external navigation via magnetic fields [5].

Despite RBCs’ commendable ability to squeeze through passages smaller than themselves, they are still around 8 μm in diameter. An E.coli bacterium, on the other hand, measures only about 2 μm in length. Consequently, designs based on RBCs attached to E.coli demonstrate limited motility and penetration ability.

Making RBCs even smaller

The current study strives to overcome this limitation by using nanoerythrosomes – smaller particles produced from RBCs. First, the researchers had isolated RBCs from murine blood. RBCs were then emptied of their cytoplasm and passed through a polycarbonate membrane with 1 μm pores. As a result, numerous nanoerythrosomes were formed with an average diameter of 350 nm. These nanoerythrosomes are, essentially, hollow vesicles that can potentially be loaded with cargo. Just as RBCs are, they are non-immunogenic, since they retain membrane proteins that make RBCs recognizable to our immune system.

To create an attachment mechanism, the researchers had genetically modified E.coli to express biotin (vitamin B7) on its membrane. The same was achieved for the nanoerythrosomes by using certain antigens to induce biotin molecules. The bacteria were then treated with molecules of streptavidin, a protein that exhibits an extremely high affinity for biotin. Biotin and streptavidin form strong non-covalent bonds. As a result, the biotin present on the bacterial membrane had connected with the biotin present on the nanoerythrosomal membrane via streptavidin molecules, creating a biotin-streptavidin-biotin bond.

Genetically engineered E. coli bacterium with nanoethryosomes

Due to the smaller size of nanoerythrosomes compared to full-grown RBCs, the resulting biohybrid microswimmers demonstrated superior motility compared to previous designs.

Fluidic drag forces acting on an E. coli-powered biohybrid microswimmer with a 4 μm cargo carrier and operating inside a physiological buffer, e.g., phosphate buffered saline (PBS), are approximately three times larger than those on a biohybrid microswimmer with a 200 nm cargo carrier operating in similar conditions. Such a decrease in fluidic drag forces acting on the biohybrid microswimmer could enhance their operation in complex biological environments with higher viscosities and smaller pore sizes.


The researchers believe that their design could lead to the efficient fabrication of personalized biohybrid microswimmers from patients’ own cells. Such objects would exhibit extremely low immunogenicity and high motility and steerability. Despite their success, the researchers contend that much more must be done from the standpoint of survivability, biotoxicity, motility, and cargo loading and release to bring biohybrid microswimmers closer to the realm of clinical use. Nanocarriers of different kinds can potentially revolutionize longevity therapies by performing early diagnostics, continuous monitoring, and targeted treatment of age-related diseases.

Please connect with us on social media, like and share our content, and help us build grass-roots support for healthy life extension: YouTube Facebook Twitter Instagram Instagram Discord
Thank You!


[1] Buss, N., Yasa, O., Alapan, Y., Akolpoglu, M. B., & Sitti, M. (2020). Nanoerythrosome-functionalized biohybrid microswimmers. APL Bioengineering4(2), 026103.

[2] Sender, R., Fuchs, S., & Milo, R. (2016). Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell164(3), 337-340.

[3] Wu, Z., Li, T., Li, J., Gao, W., Xu, T., Christianson, C., … & Wang, J. (2014). Turning erythrocytes into functional micromotors. Acs Nano8(12), 12041-12048.

[4] Hosseinidoust, Z., Mostaghaci, B., Yasa, O., Park, B. W., Singh, A. V., & Sitti, M. (2016). Bioengineered and biohybrid bacteria-based systems for drug delivery. Advanced drug delivery reviews106, 27-44.

[5] Alapan, Y., Yasa, O., Schauer, O., Giltinan, J., Tabak, A. F., Sourjik, V., & Sitti, M. (2018). Soft erythrocyte-based bacterial microswimmers for cargo delivery. Science Robotics3(17), eaar4423.

About the author
Arkadi Mazin

Arkadi Mazin

Arkadi is a seasoned journalist and op-ed author with a passion for learning and exploration. His interests span from politics to science and philosophy. Having studied economics and international relations, he is particularly interested in the social aspects of longevity and life extension. He strongly believes that life extension is an achievable and noble goal that has yet to take its rightful place on the very top of our civilization’s agenda – a situation he is eager to change.
  1. shumanpharma
    April 16, 2020

    Excellent post. I have learned a lot.

  2. jwbats
    April 19, 2020

    I’d be interested to learn what’s going on with Ido Bachelet these days.
    Five years ago, he was in the news talking about his cancer curing nanobots.
    Nowadays, you don’t hear so much about him anymore.

Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

You have 3 free articles remaining this week. You can register for free to continue enjoying the best in rejuvenation biotechnology news. Already registered? Login here.